Understanding Gastric Cancer Cells and Treatment Resistance
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance
This research aims to understand why gastric cancer becomes resistant to treatments and spreads, especially to the abdomen.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11116967 on NIH RePORTER |
What this research studies
Gastric cancer is a very serious disease that often spreads quickly and becomes resistant to current treatments. A major challenge is when the cancer spreads to the lining of the abdomen, known as peritoneal carcinomatosis, which is often very difficult to treat. We believe that the different types of cells within a tumor, and how they change over time, play a big role in how the cancer behaves and resists therapy. By looking closely at these individual cancer cells, we hope to uncover new ways to fight this aggressive disease.
Who could benefit from this research
Good fit: Patients with gastric adenocarcinoma, particularly those experiencing rapid progression, therapy resistance, or peritoneal carcinomatosis, are the focus of this research.
Not a fit: Patients with other types of cancer or those whose gastric cancer has not progressed or become resistant to therapy may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to predict how gastric cancer will behave and develop more effective treatments, especially for advanced cases.
How similar studies have performed: While the concept of tumor heterogeneity is established, this approach of focusing on tumor cell lineage plasticity using single-cell analysis to understand therapy resistance in gastric cancer is a novel and promising direction.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Wang, Linghua — University of Tx Md Anderson Can Ctr
- Study coordinator: Wang, Linghua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.